Early analyses showed response in ALCL and IMT tumours; however, only one NBL patient, who was harbouring an ALK F1174L point mutation, showed partial response with tumour shrinkage in the retroperitoneum but with simultaneous disease progression in the CNS [53]. Here, ALK is linked to inflammatory myofibroblastic tumor.